AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37091963 — intervention group
Group type: COMPARATOR
Intervention: JNJ-78436735
Number of subjects: 60
Study 37092011 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home transcranial Direct Current Stimulation (tDCS) for 20 minutes, 5 days/week for 8 weeks.
Number of subjects: 100
Study 37092011 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS procedure providing no effective stimulation.
Number of subjects: 100
Study 37092287 — intervention group
Group type: EXPERIMENTAL
Intervention: V-LAP monitoring system
Number of subjects: 30
Study 37092730 — intervention group
Group type: EXPERIMENTAL
Intervention: Czech version of the LSITA-SF12 questionnaire
Number of subjects: 1113
Study 37092829 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm thickening fraction (DTF)
Number of subjects: 13
Study 37092829 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal pressure swing (∆P es)
Number of subjects: 13
Study 37092829 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 13
Study 37092958 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium Titanyl Phosphate Laser
Number of subjects: 0
Study 37092958 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite
Number of subjects: 0
Study 37093057 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulized fecal microbiota transplantation (FMT)
Number of subjects: 22
Study 37093069 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous resection (SIMR) with major liver resection
Number of subjects: 766
Study 37093069 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous resection (SIMR) with minor liver resection
Number of subjects: 766
Study 37093069 — intervention group
Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists grades ≥3
Number of subjects: 766
Study 37093069 — intervention group
Group type: EXPERIMENTAL
Intervention: Major liver resection
Number of subjects: 766
Study 37093069 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided colectomy
Number of subjects: 766
Study 37093072 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMUNOREACT 1 cohort (therapy naive)
Number of subjects: 442
Study 37093072 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMUNOREACT 2 cohort (patients who had neoadjuvant therapy)
Number of subjects: 442
Study 37093072 — intervention group
Group type: COMPARATOR
Intervention: TGCA series
Number of subjects: 442
Study 37093072 — intervention group
Group type: COMPARATOR
Intervention: General findings
Number of subjects: 442
Study 37093074 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating fibrocyte percentage (CFP)
Number of subjects: 80
Study 37093074 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-lymphocyte ratio (NLR)
Number of subjects: 80
Study 37093160 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Cannabidiol
Number of subjects: 0
Study 37093160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37093196 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily
Number of subjects: 0
Study 37093196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37093248 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of cannabis use
Number of subjects: 0
Study 37093298 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37093350 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD70 VHH construct with C-direct-tag
Number of subjects: 0
Study 37093466 — intervention group
Group type: EXPERIMENTAL
Intervention: SYHA1402 25 mg
Number of subjects: 54
Study 37093466 — intervention group
Group type: EXPERIMENTAL
Intervention: SYHA1402 50 mg
Number of subjects: 54
Study 37093466 — intervention group
Group type: EXPERIMENTAL
Intervention: SYHA1402 100 mg
Number of subjects: 54
Study 37093466 — intervention group
Group type: EXPERIMENTAL
Intervention: SYHA1402 200 mg
Number of subjects: 54
Study 37093466 — intervention group
Group type: EXPERIMENTAL
Intervention: SYHA1402 400 mg
Number of subjects: 54
Study 37093466 — intervention group
Group type: EXPERIMENTAL
Intervention: SYHA1402 800 mg
Number of subjects: 54
Study 37093466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 37093466 — intervention group
Group type: EXPERIMENTAL
Intervention: SYHA1402 (all doses)
Number of subjects: 54
Study 37093466 — intervention group
Group type: EXPERIMENTAL
Intervention: SYHA1402 (25-100 mg)
Number of subjects: 54
Study 37093512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch adults with OSA
Number of subjects: 28
Study 37093512 — intervention group
Group type: COMPARATOR
Intervention: Chinese adults with OSA
Number of subjects: 28
Study 37093572 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal pudendal nerve block (9 mL 0.25% bupivacaine and 1 mL 40 mg/mL triamcinolone)
Number of subjects: 71
Study 37093572 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (10 mL normal saline)
Number of subjects: 71
Study 37093628 — intervention group
Group type: EXPERIMENTAL
Intervention: The Secret Trail of Moon (TSTM)
Number of subjects: 104
Study 37093628 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Chess (TC)
Number of subjects: 104
Study 37093628 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 104
Study 37093634 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative digital app via the LeoMed telecare platform for 1 month
Number of subjects: 1000
Study 37093634 — intervention group
Group type: COMPARATOR
Intervention: Standard of care without personalized digital support
Number of subjects: 1000
Study 37093641 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief barrier reduction intervention (BRI) with tailored message based on self-reported barriers (n=388)
Number of subjects: 776
Study 37093641 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (general advisory text) (n=388)
Number of subjects: 776
Study 37093641 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief barrier reduction intervention (BRI)
Number of subjects: 776
Study 37093712 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously
Number of subjects: 35
Study 37093712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 37093712 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 35
Study 37093833 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 300
Study 37093833 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 300
Study 37093833 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 300
Study 37093833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone monotherapy
Number of subjects: 300
Study 37093892 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies (nAbs) from plasma samples of SFV-infected individuals
Number of subjects: 0
Study 37093892 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies (nAbs)
Number of subjects: 0
Study 37094184 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 37094184 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37094330 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary TMA
Number of subjects: 336
Study 37094330 — intervention group
Group type: COMPARATOR
Intervention: Atypical HUS
Number of subjects: 336
Study 37094330 — intervention group
Group type: COMPARATOR
Intervention: TTP
Number of subjects: 336
Study 37094330 — intervention group
Group type: COMPARATOR
Intervention: Shigatoxin-associated HUS
Number of subjects: 336
Study 37094349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer of 1000 rupees (U.S. $12)
Number of subjects: 1120
Study 37094349 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 1120
Study 37094349 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) and Cash transfer together
Number of subjects: 1120
Study 37094336 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension-avoidance strategy
Number of subjects: 7490
Study 37094336 — intervention group
Group type: COMPARATOR
Intervention: Hypertension-avoidance strategy
Number of subjects: 7490
Study 37094596 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with rituximab
Number of subjects: 421
Study 37094668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month dual antiplatelet therapy
Number of subjects: 13136
Study 37094668 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin after 3-month dual antiplatelet therapy
Number of subjects: 13136
Study 37094692 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy (EUS-GE); technical success 97.1%, clinical success 97.1%, adverse events in 12.9% of patients, symptom recurrence 7.6% after median follow-up of 105 days.
Number of subjects: 104
Study 37094692 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy (EUS-GE)
Number of subjects: 104
Study 37094692 — intervention group
Group type: COMPARATOR
Intervention: Enteral stenting (ES)
Number of subjects: 104
Study 37094777 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-declared ERAS centres
Number of subjects: 743
Study 37094777 — intervention group
Group type: COMPARATOR
Intervention: Non-ERAS centres
Number of subjects: 743
Study 37094777 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence to ERAS pathway
Number of subjects: 743
Study 37094777 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ERAS adherence quartiles (Q1, > 60%)
Number of subjects: 743
Study 37094777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ERAS adherence quartiles (Q4, ≤ 45%)
Number of subjects: 743
Study 37094892 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy combined with therapeutic exercise for 10 weeks (two visits per week)
Number of subjects: 52
Study 37094892 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy
Number of subjects: 52
Study 37094895 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 14
Study 37094895 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 14
Study 37094943 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% Lugol's solution
Number of subjects: 242
Study 37094943 — intervention group
Group type: COMPARATOR
Intervention: 1.2% Lugol's solution
Number of subjects: 242
Study 37094945 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with T2DM
Number of subjects: 1837
Study 37094968 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient blood management program (high-dose iron supplements before and after surgery)
Number of subjects: 334
Study 37094968 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 334
Study 37094988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enadenotucirev plus nivolumab
Number of subjects: 51
Study 37094998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 8
Study 37094998 — intervention group
Group type: COMPARATOR
Intervention: Interferon β1-a
Number of subjects: 8
Study 37094997 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 33,000 IU
Number of subjects: 108
Study 37094997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 37095120 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-target CD19 CAR T-cell therapy
Number of subjects: 219
Study 37095120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-target tandem CD19/CD22 CAR T-cell therapy
Number of subjects: 219
Study 37095120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-target sequential CD19/CD22 CAR T-cell therapy
Number of subjects: 219
Study 37095120 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk factors in tandem CD19/CD22 group
Number of subjects: 219
Study 37095250 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau-targeting antisense oligonucleotide (MAPT), dosage and duration not specified
Number of subjects: 0
Study 37095285 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivized peer referral (IPR) with a $5 incentive for each peer enrolled.
Number of subjects: 0
Study 37095285 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivized peer referral (IPR)
Number of subjects: 0
Study 37095298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin use during operation (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h)
Number of subjects: 330
Study 37095298 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h)
Number of subjects: 330
Study 37095342 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat
Number of subjects: 2
Study 37095342 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 2
Study 37095378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral and inactivated-virus vaccines (heterologous combinations)
Number of subjects: 0
Study 37095378 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA vaccine as the second dose
Number of subjects: 0
Study 37095378 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated-virus vaccine (priming)
Number of subjects: 0
Study 37095378 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosting with inactivated-virus vaccine
Number of subjects: 0
Study 37095378 — intervention group
Group type: EXPERIMENTAL
Intervention: Different vaccine combinations
Number of subjects: 0
Study 37095433 — intervention group
Group type: EXPERIMENTAL
Intervention: VR meditation
Number of subjects: 24
Study 37095433 — intervention group
Group type: EXPERIMENTAL
Intervention: VR game
Number of subjects: 24
Study 37095473 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron
Number of subjects: 0
Study 37095488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic/curette subgingival instrumentation and erythritol air-polishing (test)
Number of subjects: 43
Study 37095488 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic/curette instrumentation only (control)
Number of subjects: 43
Study 37095547 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation by female investigator
Number of subjects: 245
Study 37095547 — intervention group
Group type: COMPARATOR
Intervention: Evaluation by male investigator
Number of subjects: 245
Study 37095557 — intervention group
Group type: COMPARATOR
Intervention: BI 685,509 (moderate or high dose) for 24 weeks in patients with CSPH due to alcohol-related liver disease
Number of subjects: 185
Study 37095557 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 685,509 (high dose) alone for 8 weeks in patients with hepatitis B or C virus infection or NASH
Number of subjects: 185
Study 37095557 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 685,509 (high dose) in combination with 10 mg empagliflozin for 8 weeks in patients with NASH and type 2 diabetes mellitus
Number of subjects: 185
Study 37095561 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated HCV treatment
Number of subjects: 276
Study 37095561 — intervention group
Group type: COMPARATOR
Intervention: Standard HCV treatment
Number of subjects: 276
Study 37095571 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted motivational interviewing with cognitive behavior therapy and mindfulness-based relapse prevention, delivered weekly over a period of 12 weeks.
Number of subjects: 260
Study 37095637 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 IU·kg -1 ·bw -1 epoetin β (rHuEPO)
Number of subjects: 48
Study 37095637 — intervention group
Group type: COMPARATOR
Intervention: saline (0.9% NaCl)
Number of subjects: 48
Study 37095637 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP with RET% and ABPS
Number of subjects: 48
Study 37095637 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP with IRF and IR/RBC
Number of subjects: 48
Study 37095689 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-dose triple combination therapy (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg)
Number of subjects: 245
Study 37095689 — intervention group
Group type: COMPARATOR
Intervention: Third-dose dual combination therapy (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg)
Number of subjects: 245
Study 37095689 — intervention group
Group type: COMPARATOR
Intervention: Third-dose dual combination therapy (LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg)
Number of subjects: 245
Study 37095689 — intervention group
Group type: COMPARATOR
Intervention: Third-dose dual combination therapy (AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg)
Number of subjects: 245
Study 37095689 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-dose triple combination therapy (ALC group)
Number of subjects: 245
Study 37095769 — intervention group
Group type: EXPERIMENTAL
Intervention: Single measurement of Lp(a) levels in the peri-infarction setting
Number of subjects: 0
Study 37095769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) levels six months after the initial event
Number of subjects: 0
Study 37096015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 724
Study 37096015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 37096093 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial injection of iron sucrose, median injection 90 mL (range, 70-120 mL)
Number of subjects: 20
Study 37096186 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day of raw walnut kernels for 6 months
Number of subjects: 771
Study 37096186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no walnut consumption)
Number of subjects: 771
Study 37096188 — intervention group
Group type: EXPERIMENTAL
Intervention: Gumarontinib monotherapy
Number of subjects: 84
Study 37096236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0
Study 37096396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 309
Study 37096396 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 309
Study 37096402 — intervention group
Group type: EXPERIMENTAL
Intervention: Total postoperative opioid dose (TPOD)
Number of subjects: 267
Study 37096402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sufentanil dose on postoperative day 1 (POD1)
Number of subjects: 267
Study 37096402 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with basal infusion
Number of subjects: 267
Study 37096402 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PPOI)
Number of subjects: 267
Study 37096495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 320
Study 37096495 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo, autologous FMT, no intervention, or antibiotics)
Number of subjects: 320
Study 37096777 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype #10 single-renal scallop stent-graft
Number of subjects: 547
Study 37096777 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype #15 single-renal scallop stent-graft
Number of subjects: 547
Study 37096777 — intervention group
Group type: COMPARATOR
Intervention: Standard stent-graft (control group)
Number of subjects: 547
Study 37096802 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon
Number of subjects: 997
Study 37096802 — intervention group
Group type: COMPARATOR
Intervention: PEG interferon
Number of subjects: 997
Study 37096802 — intervention group
Group type: COMPARATOR
Intervention: High-dose PEG interferon
Number of subjects: 997
Study 37096802 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon plus ribavirin
Number of subjects: 997
Study 37096802 — intervention group
Group type: COMPARATOR
Intervention: PEG interferon plus ribavirin
Number of subjects: 997
Study 37096802 — intervention group
Group type: COMPARATOR
Intervention: Grazoprevir plus elbasvir
Number of subjects: 997
Study 37096802 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir plus ribavirin plus PEG interferon
Number of subjects: 997
Study 37096956 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline solution nasal spray
Number of subjects: 0
Study 37096956 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37097109 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable alcohol biosensor
Number of subjects: 27
Study 37097283 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS Synergy intraocular lens (IOL), model ZFR00V
Number of subjects: 272
Study 37097283 — intervention group
Group type: COMPARATOR
Intervention: TECNIS IOL, model ZCB00
Number of subjects: 272
Study 37097283 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS Synergy ZFR00V
Number of subjects: 272
Study 37097283 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS Synergy ZFR00V and TECNIS IOL ZCB00
Number of subjects: 272
Study 37097330 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive right hemicolectomy (MIRH)
Number of subjects: 1095
Study 37097604 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin 5.900 IU subcutaneously twice daily in mechanically ventilated patients
Number of subjects: 43
Study 37097604 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin 5.900 IU subcutaneously once daily in patients supplemented with conventional oxygen
Number of subjects: 43
Study 37097715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab administered three-times weekly for 1 year or until progression, starting 30-45 days after TACE.
Number of subjects: 32
Study 37097715 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological responses evaluated every four cycles.
Number of subjects: 32
Study 37097726 — intervention group
Group type: EXPERIMENTAL
Intervention: Aim2Be with a live coach for 6 months
Number of subjects: 214
Study 37097726 — intervention group
Group type: COMPARATOR
Intervention: Aim2Be with no live coach (waitlist control)
Number of subjects: 214
Study 37097726 — intervention group
Group type: EXPERIMENTAL
Intervention: Aim2Be with live coaching
Number of subjects: 214
Study 37097726 — intervention group
Group type: COMPARATOR
Intervention: Aim2Be with no coaching (waitlist control)
Number of subjects: 214
Study 37097739 — intervention group
Group type: EXPERIMENTAL
Intervention: W-iCBT
Number of subjects: 182